Poly-ADP-Ribose Binding Proteins
"Poly-ADP-Ribose Binding Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins that contain POLY-ADP RIBOSE BINDING MOTIFS. They include HISTONES and other proteins that function in DNA REPAIR, replication, gene transcription, and APOPTOSIS.
| Descriptor ID |
D000075223
|
| MeSH Number(s) |
D12.776.157.687 D12.776.660.720
|
| Concept/Terms |
Poly-ADP-Ribose Binding Proteins- Poly-ADP-Ribose Binding Proteins
- Binding Proteins, Poly-ADP-Ribose
- Poly ADP Ribose Binding Proteins
- pADPr-Binding Proteins
- pADPr Binding Proteins
|
Below are MeSH descriptors whose meaning is more general than "Poly-ADP-Ribose Binding Proteins".
Below are MeSH descriptors whose meaning is more specific than "Poly-ADP-Ribose Binding Proteins".
This graph shows the total number of publications written about "Poly-ADP-Ribose Binding Proteins" by people in this website by year, and whether "Poly-ADP-Ribose Binding Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2024 | 2 | 2 | 4 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Poly-ADP-Ribose Binding Proteins" by people in Profiles.
-
Noncanonical inhibition of topoisomerase II alpha by oxidative stress metabolites. Redox Biol. 2025 Mar; 80:103504.
-
DEK :: AFF2 Fusion Sinonasal and Skull Base Nonkeratinizing Squamous Cell Carcinoma : A Clinical Outcome Study Compared With Conventional Sinonasal Squamous Cell Carcinoma. Am J Surg Pathol. 2025 Feb 01; 49(2):130-137.
-
Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma. Gynecol Oncol. 2024 Oct; 189:138-145.
-
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. Ann Oncol. 2024 Jul; 35(7):643-655.
-
Profiling of RNA-binding protein binding sites by in situ reverse transcription-based sequencing. Nat Methods. 2024 Feb; 21(2):247-258.
-
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J Neurooncol. 2018 Nov; 140(2):317-328.
-
Bromodomain and hedgehog pathway targets in small cell lung cancer. Cancer Lett. 2016 Feb 28; 371(2):225-39.
-
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol. 2015 Dec; 1(9):1319-23.
-
Molecular profiling in gastric cancer: examining potential targets for chemotherapy. J Surg Oncol. 2014 Sep; 110(3):302-6.
-
Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 02; 497(7447):67-73.